Earnings Call · Q3 FY2021·2021-11-04

Q3 21EPS +87.50%·Rev n/aQ2 21EPS -17.83%·Rev n/aQ1 21EPS +1.91%·Rev n/aQ4 20EPS -34.83%·Rev n/a⚠ consensus missing

Sarepta Therapeutics, Inc. SRPT

Mary Jenkins — Investor Relations or Communications

Doug Ingram — Chief Executive Officer (CEO)

Ian Estepan — Finance, likely CFO or Finance Officer

Dallan Murray — Executive, likely in Commercial or Sales

Gilmore O'Neill — Chief Scientific Officer (CSO)

+1.4%1d on move date+0.7% vs SPY3d−3.1%5d−2.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SRPT calls or request research access.

More SRPT calls Browse calls Request research access